denkapparat Operations GmbH Invests $426,000 in Hologic, Inc. (NASDAQ:HOLX)

denkapparat Operations GmbH purchased a new stake in Hologic, Inc. (NASDAQ:HOLX) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 5,908 shares of the medical equipment provider’s stock, valued at approximately $426,000.

Several other institutional investors have also recently bought and sold shares of the business. State Street Corp raised its holdings in shares of Hologic by 0.8% in the 3rd quarter. State Street Corp now owns 10,409,327 shares of the medical equipment provider’s stock worth $847,944,000 after acquiring an additional 81,057 shares during the last quarter. FMR LLC raised its holdings in shares of Hologic by 64.0% in the third quarter. FMR LLC now owns 5,572,545 shares of the medical equipment provider’s stock valued at $453,940,000 after purchasing an additional 2,174,093 shares during the last quarter. Victory Capital Management Inc. lifted its position in shares of Hologic by 0.5% during the fourth quarter. Victory Capital Management Inc. now owns 4,917,551 shares of the medical equipment provider’s stock valued at $354,506,000 after purchasing an additional 24,358 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. boosted its holdings in Hologic by 3.0% during the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 4,403,220 shares of the medical equipment provider’s stock worth $322,272,000 after purchasing an additional 129,035 shares during the last quarter. Finally, Boston Partners grew its position in Hologic by 81.0% during the fourth quarter. Boston Partners now owns 3,580,519 shares of the medical equipment provider’s stock valued at $257,959,000 after buying an additional 1,602,463 shares during the period. Institutional investors and hedge funds own 94.73% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently commented on HOLX shares. Raymond James reaffirmed an “outperform” rating and issued a $90.00 price target (down previously from $95.00) on shares of Hologic in a report on Thursday, February 6th. Wolfe Research assumed coverage on Hologic in a research note on Friday, December 13th. They issued a “peer perform” rating for the company. Jefferies Financial Group started coverage on shares of Hologic in a research report on Tuesday, December 10th. They issued a “hold” rating and a $85.00 price objective for the company. Argus downgraded shares of Hologic from a “buy” rating to a “hold” rating in a report on Monday, March 3rd. Finally, Stephens reissued an “overweight” rating and set a $84.00 price objective on shares of Hologic in a research note on Thursday, February 6th. Eleven equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Hologic has an average rating of “Hold” and an average price target of $84.62.

Hologic Stock Performance

Shares of HOLX stock opened at $62.32 on Friday. The company has a quick ratio of 2.78, a current ratio of 3.49 and a debt-to-equity ratio of 0.52. Hologic, Inc. has a 52 week low of $60.34 and a 52 week high of $84.67. The firm has a market capitalization of $13.98 billion, a PE ratio of 19.66, a P/E/G ratio of 2.14 and a beta of 0.97. The company has a 50 day moving average price of $65.41 and a 200-day moving average price of $73.50.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $1.03 EPS for the quarter, topping the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. As a group, equities research analysts expect that Hologic, Inc. will post 4.28 earnings per share for the current year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.